# DERM on RheumNow (June 2026)

Page: https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-june-2026
Text version: https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-june-2026.md
Podcast: [Rheumnow Podcast](https://stenobird.com/podcast/rheumnow-podcast-587987)
Published: 2026-06-26T17:39:44+00:00
Episode link: https://rheumnow.podbean.com/e/derm-on-rheumnow-june-2026/
Audio file: https://mcdn.podbean.com/mf/web/qku8877bepvymcgx/DERM_on_RheumNow_June_2026_auzod.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/rheumnow-podcast-587987/episodes/derm-on-rheumnow-june-2026
Duration seconds: 1063

## Resource

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes:- Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB, p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8. Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25). - Probiotics in Psoriatic Arthritis. (POS0290) 66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium st…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/rheumnow-podcast-587987/episodes/derm-on-rheumnow-june-2026/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-june-2026.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.